Abstracts Archive - Page 617 of 2607 - ACR Meeting Abstracts

Abstract Number: 2009 • ACR Convergence 2022
Long-term Outcome of a Treat-to-target Strategy in Elderly-onset Rheumatoid Arthritis with Chronic Lung Diseases
Manami Nomura¹, Takahiko Sugihara², Hiroyuki Baba¹, Tatsuro Ishizaki³, Tadashi Hosoya¹, Mari Kamiya¹, Takumi Matsumoto², Kanae Kubo⁴, Fumio Hirano⁵, Masayo Kojima⁶, Nobuyuki Miyasaka⁵, Shinsuke Yasuda⁵ and Masayoshi Harigai⁷, ¹Tokyo Medical and Dental University (TMDU), Tokyo, Japan, ²Department of Medicine and Rheumatology, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan, ³Human Care Research Team, Tokyo Metropolitan Institute of Gerontology., Tokyo, Japan, ⁴Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan, ⁵Department of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan, ⁶Department of Frailty Research, Center for Gerontology and Social Science, National Center for Geriatrics and Gerontology, Nagoya, Japan, ⁷Division of Rheumatology, Department of Internal Medicine, Tokyo Women’s Medical University School of Medicine, Tokyo, Japan
Background/Purpose: Elderly patients with rheumatoid arthritis (RA) tend to have a higher risk for drug-related adverse events (AEs) than younger patients, and the effectiveness and…
Abstract Number: 2018 • ACR Convergence 2022
Five Year Follow-up of Systemic Disease Activity Measured with the ESSDAI in a Standard of Care Cohort of Patients with Primary Sjögren’s Syndrome
Liseth de Wolff¹, Suzanne Arends², Alja Stel³, Greetje van Zuiden³, Jolien van Nimwegen², Arjan Vissink⁴, Frans Kroese², Gwenny Verstappen² and Hendrika Bootsma², ¹UMCG, Zwolle, Netherlands, ²University Medical Center Groningen, Groningen, Netherlands, ³University of Groningen, University Medical Centre Groningen, Groningen, Netherlands, ⁴University Medical Center Groningen, University of Groningen, Groningen, Netherlands
Background/Purpose: The EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) is often used as primary endpoint in randomised clinical trials (RCTs) in patients with primary Sjögren's…
Abstract Number: 2024 • ACR Convergence 2022
Salivary Gland Ultrasound May Lead to a More Accurate Stratification of Patients with the Same Serological Profile in Sjögren’s Syndrome: Towards a Personalized Approach
Silvia Fonzetti¹, Francesco Ferro², Gaetano La Rocca³, Giovanni Fulvio⁴, Inmaculada Concepción Navarro García⁵, Gianmaria Governato⁶, Valentina Donati⁷, Marta Mosca⁸ and Chiara Baldini⁴, ¹Azienda Ospedaliera Universitaria Pisana, Pisa, Italy, ²Clinical and Experimental Medicine Department, Azienda Ospedaliero-Universitaria Pisana, Pisa, Pisa, Italy, ³University of Pisa, Rheumatology Unit, Palermo, Palermo, Italy, ⁴University of Pisa, Pisa, Pisa, Italy, ⁵Clinical and Experimental Medicine Department, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy, ⁶Azienda Ospedaliera Universitaria Pisana, Pisa, Pisa, Italy, ⁷Pathology Unit, University of Pisa, Pisa, Italy, ⁸Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
Background/Purpose: Salivary gland ultrasound (SGUS) abnormalities have been increasingly recognized as possible biomarkers for Sjögren's Syndrome (SS) phenotypic stratification. However, to date few studies have…
Abstract Number: 2017 • ACR Convergence 2022
Characteristics and Prognosis Factors of Relapse or Death for Non-Hodgkin Lymphomas in Primary Sjögren Syndrome
Juliette Rocca¹, Maxime Beydon², Veronique Le Guern³, Eric Hachulla⁴, Jean Jacques Dubost⁵, sandrine jousse joulin⁶, Valerie Devauchelle⁷, Jacques-Eric Gottenberg⁸, Olivier Vittecoq⁹, Christian Lavigne¹⁰, Jean Schmidt¹¹, Christian Marcelli¹², Claire Larroche¹³, Xavier Mariette¹⁴, Raphaèle Seror¹⁵ and Gaetane Nocturne¹⁶, ¹APHP, Paris, France, ²Université Paris Cité, Paris, France, ³Hôpital Cochin, Paris, France, ⁴University of Lille, LILLE, France, ⁵University Hospital of Clermont Ferrand, Rheumatology, Clermont-Ferrand, France, ⁶Roche, Brest, France, ⁷Université de Bretagne Occidentale, Brest, France, ⁸University of Strasbourg, Strasbourg, France, ⁹CHU de Rouen, ROUEN, France, ¹⁰CHU Angers, Angers, France, ¹¹CHU Amiens, Amiens, France, ¹²CHU Caen, Caen, France, ¹³APHP, Bobigny, France, ¹⁴Paris-Saclay University, Rueil Malmaison, Ile-de-France, France, ¹⁵University Hospital Paris-Saclay, Le Kremlin Bicêtre, France, ¹⁶APHP, Le Kremlin Bicêtre, France
Background/Purpose: Primary Sjögren Syndrome (pSS) patients present an increased risk of Non-Hodgkin lymphoma (NHL). There is no consensus on the therapeutic management of low-grade NHL.…
Abstract Number: 2012 • ACR Convergence 2022
Predictors of Remission in Rheumatoid Arthritis Patients Treated with Biologics: A Systematic Review and Meta-analysis
Yasmin Khader, Azizullah Beran, Sami Ghazaleh, Rawish Fatima, Ashu Acharya and Nezam Altorok, University of Toledo, Toledo, OH
Background/Purpose: Biologic disease-modifying antirheumatic drugs (bDMARDs) have emerged as an effective treatment of rheumatoid arthritis (RA), improving patients’ quality of life throughout the disease course.…
Abstract Number: 2026 • ACR Convergence 2022
Serum and Tear Autoantibodies from nor Mice as Potential Diagnostic Indicators of Local and Systemic Inflammation in Sjögren’s Syndrome
Shruti Singh Kakan¹, Yaping Ju², Maria Edman² and Sarah Hamm-Alvarez³, ¹Department of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California; Department of Ophthalmology, Keck School of Medicine, Roski Eye Institute, University of Southern California, Los Angeles, CA, ²Department of Ophthalmology, Keck School of Medicine, Roski Eye Institute, University of Southern California, Los Angeles, CA, ³Department of Ophthalmology, Keck School of Medicine, Roski Eye Institute, University of Southern California; Department of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California, Los Angeles, CA
Background/Purpose: Sjögren's Syndrome (SS) is an autoimmune disease characterized by infiltration of lymphocytes into lacrimal (LG) and salivary (SG) glands and their concurrent loss of…
Abstract Number: 2016 • ACR Convergence 2022
Safety and Efficacy Associated with Long-Term Low Dose Glucocorticoids in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials
Andriko Palmowski¹, Sabrina Mai Nielsen², Zhivana Boyadzhieva³, Abelina Schneider³, Anne Pankow³, Linda Hartman⁴, Jose Pereira da Silva⁵, John Kirwan⁶, Siegfried Wassenberg⁷, Christian Dejaco⁸, Robin Christensen⁹, Maarten Boers¹⁰ and Frank Buttgereit¹¹, ¹Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ²The Parker Institute, Section for Biostatistics and Evidence-Based Research, Bispebjerg-Frederiksberg Hospital, Frederiksberg, Denmark, ³Charité-Universitätsmedizin Berlin, Berlin, Germany, ⁴Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam, Netherlands, ⁵University of Coimbra, Rheumatology, Columbia, Portugal, ⁶University of Bristol, Bristol, United Kingdom, ⁷Rheumazentrum Ratingen, Ratingen, Germany, ⁸Department of Rheumatology, Hospital of Brunico (SABES-ASDAA), Brunico, Italy, and Department of Rheumatology and Immunology, Medical University of Graz, Graz, Austria, ⁹Musculoskeletal Statistics Unit, The Parker Institute, Copenhagen, Denmark, ¹⁰Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands, ¹¹Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin / DRFZ Berlin, Berlin, Germany
Background/Purpose: There is ongoing controversy about the safety and efficacy of long-term low dose glucocorticoids (GCs) in rheumatoid arthritis (RA). Our aim was to study…
Abstract Number: 2022 • ACR Convergence 2022
Outcome of Pregnancy in Women with Primary Sjögren’s Syndrome Compared to the General Population: The French Multicenter Prospective GR2 Study
Gregoire Martin de Fremont¹, Nathalie Costedoat-Chalumeau², Rakiba Belkhir³, Gaelle Guettrot-Imbert⁴, Nathalie Morel⁴, Gaetane Nocturne⁵, Anna Molto⁶, Tiphaine Goulenok⁷, Elisabeth Diot⁸, Estibaliz Lazaro⁹, Laurent Perard¹⁰, Nicole Ferreira¹¹, Maelle Le Besnerais¹², Nicolas Limal⁷, Nihal Martis¹³, Noémie Abisror¹⁴, Odile Debouverie¹⁵, Christophe Richez¹⁶, Vincent Sobanski¹⁷, Francois Maurier¹⁸, Gaetan Sauvetre¹², Herve Levesque¹², Marie Agnes Timsit¹⁹, Nathalie Tieule¹³, Pauline Orquevaux²⁰, GEFA Collaborative group²¹, Matthieu Mahevas²², Celine Lartigau Roussin²³, Elodie Chauvet²⁴, Emilie Berthoux²⁵, Francoise Sarrot Reynauld²⁶, Loic Raffray²⁷, Marion Couderc²⁸, Nicolas Martin Silva²⁹, Noemie Jourde Chiche³⁰, Nicolas Belhomme³¹, Thierry Thomas³², Vincent Poindron³³, Viviane Queyrel¹³, Juliette Delforge³⁴, Camille Le Ray³⁵, Emmanuelle Pannier³⁵, Xavier Mariette³⁶, Veronique Le Guern⁴ and Raphaèle Seror³⁷, ¹Rheumatology department, Kremlin Bicêtre hospital, APHP, Paris, France, ²Inserm DR Paris 5, Paris, France, ³Rheumatology departement, Bicêtre, Paris-Saclay university, Le Kremlin Bicêtre, France, ⁴Hôpital Cochin, Paris, France, ⁵APHP, Le Kremlin Bicêtre, France, ⁶Rheumatology Department, Cochin Hospital, APHP, Paris, France, ⁷APHP, Paris, France, ⁸CHU Tours, Tours, France, ⁹Bordeaux Hospital University, Bordeaux, France, ¹⁰CHU Lyon, Lyon, France, ¹¹department of Internal Medecine, CHU de Tours, Tours, France, ¹²CHU Rouen, Rouen, France, ¹³CHU Nice, Nice, France, ¹⁴Hopital Saint Antoine, Paris, France, ¹⁵CHU Poitiers, Poitiers, France, ¹⁶Université de Bordeaux, Bordeaux, France, ¹⁷Université de Lille, Lille, France, ¹⁸Hôpitaux privés de Metz, Metz, France, ¹⁹CHU Brest, Brest, France, ²⁰CHU Reims, Reims, France, ²¹Saint Joseph Hospital, Marseille, France, ²²CHU Mondor, Creteil, France, ²³CH La Réunion, CH la Réunion, France, ²⁴CH Cabestany, Cabestany, France, ²⁵CH Saint Joseph Saint Luc, Lyon, France, ²⁶CHU Grenoble, CHU Grenoble, France, ²⁷CH St Denis Reunion, Saint Denis Reunion, France, ²⁸University Hospital, Clermont-Ferrand, France, ²⁹CHU Caen, Caen, France, ³⁰APHM, Marseille, France, ³¹CHU Rennes, Rennes, France, ³²CHU Saint Etienne, Saint Etienne, France, ³³Immunologie clinique et médecine interne, Hôpitaux universitaires de Strasbourg, Strasbourg, France, ³⁴Jean Verfier, Bobigny, France, ³⁵Port Royal, Paris, France, ³⁶Paris-Saclay University, Rueil Malmaison, Ile-de-France, France, ³⁷University Hospital Paris-Saclay, Le Kremlin Bicêtre, France
Background/Purpose: In the context of primary Sjögren's syndrome (pSS), only a few retrospective studies using heterogeneous methods have investigated the risk of adverse pregnancy outcomes…
Abstract Number: 2025 • ACR Convergence 2022
Natural History of Sjögren’s Disease from the National Institutes of Health Cohort
Brandon Law¹, Margaret Beach², Eileen Pelayo², Ilias Alevizos², Zohreh Khavandgar², Blake Warner² and Alan Baer¹, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²National Institutes of Health, Bethesda, MD
Background/Purpose: The objectives of this study were to assess the natural history of Sjögren's disease (SjD) over an interval reaching up to 32 years among…
Abstract Number: 2032 • ACR Convergence 2022
Major Salivary Gland Ultrasound and Elastography for Assessment of Disease Activity in Patients of Primary Sjögren’s Syndrome
Kunal Chandwar¹, Juhi Dixit¹, Kriti Kishor¹, DOGGA PRASANNA KUMAR², DIGVIJAY EKBOTE³, PUNEET KUMAR¹ and Urmila Dhakad¹, ¹King George's Medical University, Lucknow, India, ²KGMU, LUCKNOW, Uttar Pradesh, India, ³KING GEORGE MEDICAL UNIVERSITY, LUCKNOW, Uttar Pradesh, India
Background/Purpose: To assess major salivary gland involvement by ultrasonography and elastography in patients with Sjögren's syndrome , compare it with controls and correlate the severity…
Abstract Number: 2034 • ACR Convergence 2022
What Is the Best Initial Screening for Suspected Sjögren’s Disease?
Katja Perdan Pirkmajer, Jelka Kramarič, matija Tomšič and Alojzija Hocevar, University Medical Centre Ljubljana, Ljubljana, Slovenia
Background/Purpose: During the COVID-19 pandemic the routine diagnostic procedure in Sjögren's disease (SS) was highly hampered. The aim of our study was to determine in…
Abstract Number: 2033 • ACR Convergence 2022
Novel Autoantibodies Identified in Seronegative Sjögren’s Disease Using Innovative Whole Peptidome Array Technology
Maxwell Parker, Zihao Zheng, Quinn Parker, Addie Vande Loo, Michael Newton, Miriam Shelef and Sara McCoy, University of Wisconsin, Madison, WI
Background/Purpose: SjD disease (SjD) is typically diagnosed by the presence of an anti-SSA antibody or focal lymphocytic sialadenitis in salivary gland tissue. Among SjD patients…
Abstract Number: 2028 • ACR Convergence 2022
The Value of FDG-PET/CT in the Detection of Lymphomas Associated with Primary Sjögren’s Syndrome
Martha S. van Ginkel¹, Andor WJM Glaudemans¹, Bert van der Vegt¹, Arjan Vissink¹, Frans Kroese² and Hendrika Bootsma², ¹University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ²University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: Primary Sjögren's syndrome (pSS) patients have an increased risk of developing a lymphoma. PSS-associated lymphomas are mostly of the mucosa associated lymphoid tissue (MALT)…
Abstract Number: 1986 • ACR Convergence 2022
Early-stage Rheumatoid Arthritis Patients with High Levels of Type III Collagen Are Less Likely to Respond to Anti-IL6R Treatment
Sofie Falkenløve Madsen¹, Dovile Sinkeviciute², Christian Thudium², Morten Karsdal² and Anne-Christine Bay-Jensen², ¹University of Copenhagen / Nordic Bioscience, Herlev, Denmark, ²Nordic Bioscience, Herlev, Denmark
Background/Purpose: Rheumatoid arthritis (RA) is a chronic, autoimmune disease, which normally is characterized by inflammation and thickening of the synovial membrane leading to swollen and…
Abstract Number: 1985 • ACR Convergence 2022
The BEGIN Study: A Double-blind, Multi-center, Two-part, Randomized, Placebo-controlled Study of the Safety, Tolerability, and Efficacy of 4 Weeks of Treatment with AP1189 in Early Rheumatoid Arthritis (RA) Patients with Active Joint Disease
Thomas Jonassen¹, Irene Sandholdt², Birgitte Telmer² and Ellen-Margrethe Hauge³, ¹SynAct Pharma, Holte, Denmark, ²CroxxMed, Hørsholm, Denmark, ³Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark
Background/Purpose: Melanocortin (MC) type 1 and type 3 receptor stimulation is associated with anti-inflammatory activity and the promotion of inflammatory resolution. AP1189 is novel biased…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].